{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T01:58:52Z","timestamp":1778983132560,"version":"3.51.4"},"reference-count":39,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009818","name":"State Styria, Department 12 Economy, Tourism, Science and Research","doi-asserted-by":"publisher","award":["ABT12-319238\/2024"],"award-info":[{"award-number":["ABT12-319238\/2024"]}],"id":[{"id":"10.13039\/501100009818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: to evaluate our real-world data on the efficacy and safety of switching between two monoclonal antibodies in biologic treatment of uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Methods: All patients receiving biologic treatment for uncontrolled CRSwNP between April 2020 and March 2024 at a tertiary referral center who needed transitioning between biologic agents were retrospectively analyzed. The following parameters were investigated: patient\u2019s clinical characteristics, wash-out periods, treatment outcome, and switching-related side effects. Results: Out of 91 CRSwNP patients who received biologic treatment, 4 patients (4.4%) necessitated switching to an alternative biologic agent. Three patients were switched to a different antibody because of insufficient symptom control with the initially prescribed biologic, while the other patient required switching to an alternative agent due to a side effect. Switching resulted in all four patients achieving a significant improvement in all outcome parameters. There were no switching-related side effects, and the switching procedure was performed in three cases without a wash-out period. Conclusion: CRSwNP patients under biologic therapy with an insufficient response or medication-related side effect may benefit from switching to an alternative biologic agent. Larger, prospective multicenter studies are warranted to further validate the effectiveness and safety of switching agents in the biologic treatment of CRSwNP.<\/jats:p>","DOI":"10.3390\/jcm13226883","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T08:28:13Z","timestamp":1731659293000},"page":"6883","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Monoclonal Antibody Switching in Biologic Treatment of Chronic Rhinosinusitis with Nasal Polyps"],"prefix":"10.3390","volume":"13","author":[{"given":"Michael","family":"Habenbacher","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Moser","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Hadl","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9187-2063","authenticated-orcid":false,"given":"Peter","family":"Kiss","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Holzmeister","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Pock","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Walla","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2530-9931","authenticated-orcid":false,"given":"Alexandros","family":"Andrianakis","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/000348940311200709","article-title":"Prevalence of nasal polyps in adults: The Sk\u00f6vde population-based study","volume":"112","author":"Johansson","year":"2003","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"ref_3","first-page":"173","article-title":"Clinical factors influencing the eosinophil infiltration of nasal polyps","volume":"40","author":"Jankowski","year":"2002","journal-title":"Rhinology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper","volume":"74","author":"Kowalski","year":"2019","journal-title":"Allergy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4193\/Rhin22.408","article-title":"Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD","volume":"61","author":"Brkic","year":"2023","journal-title":"Rhinology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jaci.2006.09.005","article-title":"Rhinosinusitis Initiative Rhinosinusitis: Developing guidance for clinical trials","volume":"118","author":"Meltzer","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","first-page":"194","article-title":"EPOS\/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"De Corso, E., Settimi, S., Montuori, C., Corb\u00f2, M., Passali, G.C., Porru, D.P., Lo Verde, S., Spanu, C., Penazzi, D., and Di Bella, G.A. (2022). Effectiveness of dupilumab in the treatment of patients with severe uncontrolled CRSwNP: A \u201cReal-life\u201d observational study in the first year of treatment. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102684"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/all.15134","article-title":"Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps","volume":"77","author":"Fokkens","year":"2022","journal-title":"Allergy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/all.14809","article-title":"Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000519228","article-title":"Which is the best biologic for nasal polyps: Dupilumab, omalizumab, or mepolizumab? a network meta-analysis","volume":"183","author":"Wu","year":"2021","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/1744666X.2023.2218617","article-title":"Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making","volume":"19","author":"Otten","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Dorling, M., Sarafan, M., Voizard, B., Ammar, Y.A., Hernaiz-Leonardo, J.C., Chalmers, K., MacInnis, P., Nugent, J., Janjua, A., and Javer, A. (2024). Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience. Int. Forum Allergy Rhinol, ahead of print.","DOI":"10.1002\/alr.23466"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11882-023-01106-w","article-title":"Omalizumab Treatment in Uncontrolled Asthma and CRSwNP Patients, with Previous Endoscopic Sinus Surgery, to Improve Quality of Life and Endoscopic Outcomes: A Two-Year Real-Life Study","volume":"23","author":"Cuvillo","year":"2023","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_17","first-page":"245","article-title":"The Efficacy of Omalizumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Severe Allergic Asthma","volume":"23","author":"Atayik","year":"2024","journal-title":"Iran J. Allergy Asthma Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_19","unstructured":"(2024, September 10). Available online: https:\/\/www.sozialversicherung.at\/oeko\/views\/index.xhtml."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13223-023-00823-1","article-title":"Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada","volume":"19","author":"Yong","year":"2023","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/all.14547","article-title":"Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the Treatment of Multiple Food Allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_23","unstructured":"(2024, September 10). Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/development-approval-process-cber\/biological-approvals-year."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s00405-024-08461-y","article-title":"Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP","volume":"281","author":"Rosso","year":"2024","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Higo, H., Ichikawa, H., Arakawa, Y., Mori, Y., Itano, J., Taniguchi, A., Senoo, S., Kimura, G., Tanimoto, Y., and Miyake, K. (2023). Switching to Dupilumab from Other Biologics without a Treatment Interval in Patients with Severe Asthma: A Multi-Center Retrospective Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12165174"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1753466620929231","DOI":"10.1177\/1753466620929231","article-title":"Foschino Barbaro MP. Switching from omalizumab to mepolizumab: Real-life experience from Southern Italy","volume":"14","author":"Carpagnano","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Dorling, M., Hernaiz-Leonardo, J.C., Pascual, A., Janjua, A., Thamboo, A., and Javer, A. (2024). Real-World Adverse Events After Type 2 Biologic use in Chronic Rhinosinusitis with Nasal Polyps. Laryngoscope, ahead of print.","DOI":"10.1002\/lary.31541"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.21911\/aai.2023170","article-title":"Should There be a Washout Period When Switching to Another Biological in Asthma?","volume":"21","author":"Cetin","year":"2023","journal-title":"Asthma Allergy Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4155\/ipk-2016-0012","article-title":"Pharmacokinetics definitions in regulatory documents: Transfer from small molecules into biologics","volume":"1","author":"Grabowski","year":"2016","journal-title":"Int. J. Pharmacokinet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/cea.13809","article-title":"Switching between biologics in severe asthma patients. When the first choice is not proven to be the best","volume":"51","author":"Papaioannou","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e1511","DOI":"10.1002\/cti2.1511","article-title":"Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of gender: Results from the SINUS-52 trial","volume":"13","author":"Fokkens","year":"2024","journal-title":"Clin. Transl. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/alr.21667","article-title":"Gender-specific differences in chronic rhinosinusitis patients electing endoscopic sinus surgery","volume":"6","author":"Lal","year":"2016","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/01945998221076468","article-title":"Examination of Sex Differences in a Chronic Rhinosinusitis Surgical Cohort","volume":"167","author":"Ramos","year":"2022","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1017\/S0022215107001302","article-title":"Impact of gender on clinical presentation of chronic rhinosinusitis with and without polyposis","volume":"122","author":"Busaba","year":"2008","journal-title":"J. Laryngol. Otol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/iid3.46","article-title":"A retrospective, cross-sectional study reveals that women with CRSwNP have more severe disease than men","volume":"3","author":"Stevens","year":"2015","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00405-020-06418-5","article-title":"Differences in men and women suffering from CRSwNP and AERD in quality of life","volume":"278","author":"Bartosik","year":"2021","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2500\/ar.2015.6.0120","article-title":"Commentary on gender differences in prevalence, treatment, and quality of life of patients with chronic rhinosinusitis","volume":"6","author":"Ference","year":"2015","journal-title":"Allergy Rhinol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Mullol, J., Sastre, J., Dom\u00ednguez-Ortega, J., Aparicio, M.B., Vizuete, J.A.C., Alobid, I., Garc\u00eda-Vitoria, M., and I Palomo-Jim\u00e9nez, P. (2024). Prevalence of chronic rhinosinusitis without\/with nasal polyps according to severity in Spain. Rhinology, ahead of print.","DOI":"10.4193\/Rhin23.341"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaip.2018.10.014","article-title":"Clinical Characteristics of Patients with Chronic Rhinosinusitis without Nasal Polyps in an Academic Setting","volume":"7","author":"Benjamin","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6883\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:33:11Z","timestamp":1760113991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":39,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13226883"],"URL":"https:\/\/doi.org\/10.3390\/jcm13226883","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}